-
2024 ACS Green Chemistry Institute Ignition Grant
The ACS Green Chemistry Institute Pharmaceutical Roundtable (GCIPR) is seeking to provide ‘ignition’ funding for novel and innovative ideas that have the potential to provide sustainable solutions to chemistry and engineering problems relevant to the pharmaceutical industry from discovery to manufacturing. The goal is to provide researchers with initial funding to obtain preliminary results that […]
-
Grants in support of projects in the Humanities, Social Sciences and Biomedicine fields
Fritz Thyssen Foundation invites applications for its research grants. An application can be filed in the following areas of support: • History, language & culture • State, economy & society • Medicine and natural sciences Interdisciplinary projects are also welcomed by the foundation. The planned project can generally stretch over a working period of up to […]
-
Drug repurposing in MND
LifeArc will fund high quality innovative proposals that set out a rigorous evidence-based approach to the preclinical translation of repurposed drug candidates and drug candidate combinations, uniquely including funding for independent replication of project results through LifeArc. Applicants should focus their proposals on the preclinical stage of drug discovery and development for repurposed drug candidates. […]
-
JRC Research Infrastructures – 3 new calls launched for Training and Capacity Building
The JRC launched 3 calls for Training and Capacity Building within our Open Access to JRC Research Infrastructures. The Calls are published in the Science Hub Portal under: https://joint-research-centre.ec.europa.eu/calls-proposals/2024-1-tcb-elsa-reactionwall_en https://joint-research-centre.ec.europa.eu/calls-proposals/2024-1-tcb-elsa-hoplab_en https://joint-research-centre.ec.europa.eu/calls-proposals/2024-1-tcb-nanobiotech_en ELSA – European-laboratory-structural-assessment-reaction-wall Reference: 2024-1-TCB-ELSA-ReactionWall Location: Ispra, (Italy) Deadline date: 14 May 2024, 23:59 (CEST) ELSA – European-laboratory-structural-assessment-large-hopkinson-bar-facility Reference: 2024-1-TCB-ELSA-HOPLAB Location: Ispra, (Italy) Deadline […]
-
Tuberous Sclerosis Complex Research Grants
The TSC Alliance invests in early-career researchers to drive innovative Tuberous sclerosis complex (TSC) research and to foster a diverse group of researchers dedicated to their shared mission. Research grant proposals should address one of the following four high-priority areas: Understanding phenotypic heterogeneity in TSC, i.e., research on genetic, biologic, or environmental factors that might […]
-
TSC Alliance
The TSC Alliance is an internationally recognized nonprofit that does everything it takes to improve the lives of people with TSC (Tuberous sclerosis complex).
-
ERC 2024 Advanced Grant: Call Information Webinar 1 of 2
Date: 10 June 2024 Time: 10:00 to 12:00 UK time Event type: Webinar Cost: Free Register to attend UKRO, in its capacity as UK NCP for the European Research Council, will hold a webinar on the ERC 2024 Advanced Grant call. Aim of the event The webinar will provide participants with a detailed practical overview […]
-
Alzheimer’s Drug Discovery Foundation Therapeutics Funding Programs
The Alzheimer’s Drug Discovery Foundation (ADDF) is offering 3 funding opportunities: Drug Development Program: The Drug Development program supports investigational new drug (IND)-enabling studies (or the international equivalent) and early-phase clinical trials that test promising pharmacological interventions and devices for Alzheimer’s disease (AD) and related dementias. Both disease-modifying and symptomatic agents will be considered. This […]
-
תגמול חוקרות וחוקרים על הגשה וזכיה במענקי ERC
חוקר/ת יקר/ה, בהמשך לפגישות פורום נמ”ר בנושא תגמול חוקרות וחוקרים על הגשה וזכיה במענקי ERC, מצ”ב מכתבו של נשיא אוניברסיטת בר-אילן פרופ’ אריה צבן בנידון, לידיעתך: תגמול חוקרות וחוקרים על הגשה וזכיה במענקי ERC בברכה, רשות המחקר
-
Dr. Shira Peleg
-
Dr. Zufit Hexner-Erlichman
-
Accelerating Drug Discovery for Frontotemporal Degeneration
There are currently no FDA approved disease-modifying treatments available for frontotemporal dementia (FTD), and symptomatic treatments only provide limited benefit for patients. Recent scientific advances have provided an increased understanding of pathogenic mechanisms underlying FTD and are driving the development of potential disease-modifying therapies. The Alzheimer’s Drug Discovery Foundation (ADDF) and The Association for Frontotemporal […]